COSCIENS Reconciled Depreciation from 2010 to 2024

CSCI Stock   2.90  0.05  1.75%   
COSCIENS Biopharma's Reconciled Depreciation is increasing with slightly volatile movements from year to year. Reconciled Depreciation is estimated to finish at about 1.6 M this year. For the period between 2010 and 2024, COSCIENS Biopharma, Reconciled Depreciation quarterly trend regression had mean deviation of  22,790 and range of 185.3 K. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2010-12-31
Previous Quarter
1.5 M
Current Value
1.6 M
Quarterly Volatility
40.8 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check COSCIENS Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among COSCIENS Biopharma's main balance sheet or income statement drivers, such as Net Interest Income of 200.3 K, Interest Expense of 89.8 K or Selling General Administrative of 3.7 M, as well as many indicators such as . COSCIENS financial statements analysis is a perfect complement when working with COSCIENS Biopharma Valuation or Volatility modules.
  
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.

Latest COSCIENS Biopharma's Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of COSCIENS Biopharma over the last few years. It is COSCIENS Biopharma's Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in COSCIENS Biopharma's overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

COSCIENS Reconciled Depreciation Regression Statistics

Arithmetic Mean1,455,050
Geometric Mean1,454,541
Coefficient Of Variation2.80
Mean Deviation22,790
Median1,443,766
Standard Deviation40,811
Sample Variance1.7B
Range185.3K
R-Value0.45
Mean Square Error1.4B
R-Squared0.20
Significance0.1
Slope4,065
Total Sum of Squares23.3B

COSCIENS Reconciled Depreciation History

20241.6 M
20231.5 M
20221.4 M
20211.5 M

About COSCIENS Biopharma Financial Statements

Investors use fundamental indicators, such as COSCIENS Biopharma's Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Although COSCIENS Biopharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Reconciled Depreciation1.5 M1.6 M

Currently Active Assets on Macroaxis

When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.69)
Revenue Per Share
3.759
Quarterly Revenue Growth
0.041
Return On Assets
(0.23)
Return On Equity
(0.66)
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.